These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 16291211

  • 21. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N, Keilholz U, Nichol G, Cancer Vaccine Clinical Trial Working Group.
    J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
    [Abstract] [Full Text] [Related]

  • 22. Use of attenuated bacteria as delivery vectors for DNA vaccines.
    Daudel D, Weidinger G, Spreng S.
    Expert Rev Vaccines; 2007 Feb; 6(1):97-110. PubMed ID: 17280482
    [Abstract] [Full Text] [Related]

  • 23. Dendritic cell vaccines in melanoma: from promise to proof?
    Lesterhuis WJ, Aarntzen EH, De Vries IJ, Schuurhuis DH, Figdor CG, Adema GJ, Punt CJ.
    Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
    [Abstract] [Full Text] [Related]

  • 24. Heat-shock protein-based vaccines for cancer and infectious disease.
    Binder RJ.
    Expert Rev Vaccines; 2008 Apr; 7(3):383-93. PubMed ID: 18393608
    [Abstract] [Full Text] [Related]

  • 25. Production of clinical-grade plasmid DNA for human Phase I clinical trials and large animal clinical studies.
    Przybylowski M, Bartido S, Borquez-Ojeda O, Sadelain M, Rivière I.
    Vaccine; 2007 Jun 28; 25(27):5013-24. PubMed ID: 17537555
    [Abstract] [Full Text] [Related]

  • 26. Plasmid DNA and viral vector-based vaccines for the treatment of cancer.
    Anderson RJ, Schneider J.
    Vaccine; 2007 Sep 27; 25 Suppl 2():B24-34. PubMed ID: 17698262
    [Abstract] [Full Text] [Related]

  • 27. The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses.
    Barouch DH, Letvin NL, Seder RA.
    Immunol Rev; 2004 Dec 27; 202():266-74. PubMed ID: 15546399
    [Abstract] [Full Text] [Related]

  • 28. New approaches in vaccine development.
    Leclerc C.
    Comp Immunol Microbiol Infect Dis; 2003 Oct 27; 26(5-6):329-41. PubMed ID: 12818620
    [Abstract] [Full Text] [Related]

  • 29. Assuring the quality, safety, and efficacy of DNA vaccines.
    Robertson JS, Griffiths E.
    Mol Biotechnol; 2001 Feb 27; 17(2):143-9. PubMed ID: 11395863
    [Abstract] [Full Text] [Related]

  • 30. The immunogenicity of viral haemorragic septicaemia rhabdovirus (VHSV) DNA vaccines can depend on plasmid regulatory sequences.
    Chico V, Ortega-Villaizan M, Falco A, Tafalla C, Perez L, Coll JM, Estepa A.
    Vaccine; 2009 Mar 18; 27(13):1938-48. PubMed ID: 19368775
    [Abstract] [Full Text] [Related]

  • 31. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha.
    Jiang W, Ren L, Jin N.
    J Virol Methods; 2007 Dec 18; 146(1-2):266-73. PubMed ID: 17868910
    [Abstract] [Full Text] [Related]

  • 32. DNA plasmid vaccination for multiple sclerosis.
    Stüve O, Eagar TN, Frohman EM, Cravens PD.
    Arch Neurol; 2007 Oct 18; 64(10):1385-6. PubMed ID: 17923622
    [No Abstract] [Full Text] [Related]

  • 33. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
    Ohlschläger P, Pes M, Osen W, Dürst M, Schneider A, Gissmann L, Kaufmann AM.
    Vaccine; 2006 Apr 05; 24(15):2880-93. PubMed ID: 16472545
    [Abstract] [Full Text] [Related]

  • 34. DNA vaccination for prostate cancer.
    Roos AK, King A, Pisa P.
    Methods Mol Biol; 2008 Apr 05; 423():463-72. PubMed ID: 18370222
    [Abstract] [Full Text] [Related]

  • 35. DNA vaccination and gene therapy: optimization and delivery for cancer therapy.
    Bodles-Brakhop AM, Draghia-Akli R.
    Expert Rev Vaccines; 2008 Sep 05; 7(7):1085-101. PubMed ID: 18767956
    [Abstract] [Full Text] [Related]

  • 36. Plasmid DNA- and messenger RNA-based anti-cancer vaccination.
    Weide B, Garbe C, Rammensee HG, Pascolo S.
    Immunol Lett; 2008 Jan 15; 115(1):33-42. PubMed ID: 18006079
    [Abstract] [Full Text] [Related]

  • 37. Engineering enhancement of the immune response to HBV DNA vaccine in mice by the use of LIGHT gene adjuvant.
    Zhang Y, Jiang W, Fan Y, Wen J, Hao W, Qian M.
    J Virol Methods; 2008 Nov 15; 153(2):142-8. PubMed ID: 18722475
    [Abstract] [Full Text] [Related]

  • 38. Designer adjuvants for enhancing the efficacy of infectious disease and cancer vaccines based on suppression of regulatory T cell induction.
    Mills KH.
    Immunol Lett; 2009 Feb 21; 122(2):108-11. PubMed ID: 19100777
    [Abstract] [Full Text] [Related]

  • 39. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines.
    Ishii KJ, Kawagoe T, Koyama S, Matsui K, Kumar H, Kawai T, Uematsu S, Takeuchi O, Takeshita F, Coban C, Akira S.
    Nature; 2008 Feb 07; 451(7179):725-9. PubMed ID: 18256672
    [Abstract] [Full Text] [Related]

  • 40. Intramuscular DNA vaccination protocols mediated by electric fields.
    Chiarella P, Signori E.
    Methods Mol Biol; 2014 Feb 07; 1121():315-24. PubMed ID: 24510835
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.